Ofatumumab, Methylprednisone, Lenalidomide Regimen Feasible as Frontline Therapy in CLL/SLL : vimarsana.com

Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies.

Related Keywords

Sebastian Kaulitzki , Abbvie Genentech , Eva Sahakian , Novartis , H Lee Moffitt Cancer Center , Research Institute , Clinical Lymphoma , Moffitt Cancer Center ,